Marker Therapeutics Inc (MRKR) Company Profile & Statistics

Marker Therapeutics Inc
MRKR
(Nasdaq - US)
N/A
4.16
+0.11 (+2.72%)
in:usd•As of: May 01, 2024 15:04 UTC -4
Open
4.10
High
4.16
Low
4.10

About Marker Therapeutics Inc

CEO

Juan Vera

Headquarters

9350 kirby drive, suite 300

houston, tx 77054, united states

Auditor

Marcum LLP

Employees

Share Holders

Website

www.markertherapeutics.com

Industry

biotechnology

Sector

health technology

Company Overview

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment and eradication of cancer, including metastatic cancer. The company's product pipeline consists of MultiTAA T Cell Therapy, TPIV200 and TPIV100/110 which are in clinical stage. Marker Therapeutics Inc., formerly known as TapImmune Inc., is based in FL, United States.

Marker Therapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	37.07M
Enterprise Value	21.95M
Enterprise Value/EBITDA (ttm)	-1.61
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	2.56
Price to Sales (ttm)	5.54
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	-106.59%
Profit Margin (ttm)	-204.48%
Return on Equity (ttm)	-39.89%
Return on Invested Capital (ttm)	-84.81%
Return on Assets (ttm)	-25.45%

Income Statement

Revenue (ttm)	3.31M
Revenue Per Share (ttm)	0.37
Gross Profit (ttm)	3.31M
EBITDA (ttm)³	-13.61M
Net Income Avi to Common (ttm)	-8.24M
Diluted EPS (ttm)	N/A

Share Statistics

Beta (5Y Monthly)	1.54
52-Week Change	268.14%
S&P500 52-Week Change	24.90%
S&P500 Member	No
Stock Optionable	No
Total Shares Outstanding ¹	8.90M
Dividend Yield	0.00%
Float ⁴	6.76M
% Held by Insiders	24.10%
% Held by Institutions	22.39%

Balance Sheet

Total Cash (mrq)	15.11M
Total Cash Per Share (mrq)	1.70
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	5.57%
Quick Ratio (mrq)	5.57%
Book Value Per Share (mrq)	1.58

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.87
Free Cash Flow (ytd)	-16.44M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Marker Therapeutics Inc

Trade With A Regulated Broker